HeartCare Medical Files for Hong Kong IPO, Submits Overseas Listing Application to CSRC

Source: Capital Bond

On January 22, Capital Bond learned that the International Department of the China Securities Regulatory Commission (CSRC) recently disclosed the application materials submitted by Shanghai HeartCare Medical Technology Co., Ltd. (hereinafter referred to as “HeartCare”) for approval of its initial public offering of shares overseas (including various types of shares such as ordinary shares and preferred shares, as well as share-derived instruments).

Once accepted, it means that HeartCare has obtained the "small pass" and can soon be inHKEXSubmit the prospectus.

According to Tianyancha, HeartCare, established in 2016, is an innovative enterprise focused on the development and industrialization of new minimally invasive interventional technologies for the prevention and treatment of stroke. Its product line includes thrombectomy treatments for ischemic stroke, treatments for ischemic stroke stenosis, treatments for hemorrhagic stroke, prevention of cardioembolic stroke, and vascular access products.

The company had previously completed five rounds of financing, including three equity financing rounds last year alone. Investors in HeartCare include CICC Pucheng,Fosun Pharma, SDIC Chuanghe and other investment institutions.

Header image source: Tuchong

Reprint Statement: This article is an original work by CapitalBang. Please cite the source and author when reprinting; otherwise, it will be considered infringement.

Risk Warning: All information presented by Capital Bond is for reference only and does not constitute investment advice. No information regarding investment operations shall be relied upon as a basis for making investment decisions. Investments carry risks; please exercise caution when entering the market!